Production and import of bulk drugs

1342. SHRIMATI PRATIBHA SINGH :
SHRI H. HANUMANTHAPPA :

Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question 635 given in the Rajya Sabha on the 14th May, 1990 and state :

(a) whether it is a fact that inspite of liberalisation, production of 29 bulk drugs out of around 70 bulk drugs for which production is monitored has fallen ;

(b) what was the production of each of these 29 drugs during the last four years, year-wise and what is the extent of shortfall from 1986-87 production :

(c) what are the names of total monitored bulk drugs, which are being produced from intermediate stage and since when ;

(d) what was the production of intermediate stage produced drugs during the last three years, year-wise :

(e) whether it is a fact that the import of bulk drugs, finished medicines and intermediates has been given a boost under 1986 Drug Policy ; and

(f) if so, what is the total import of each during 1986-87 and 1989-90 ?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY) : (a) to (d) Fall in production of any drug is a function of several factors including demand, availability of viable technology and the corporate plans of the company. Several monitored drugs such as Ethambutol, Rifampicin, Pyrazinamide, Chloroquine, Amodiaquine etc. are being produced from the intermediate stage since several years. Details of production of all monitored drugs are published regularly in the Annual Performance Budgets of this Ministry, which are available in the Parliament Library.

(e) No Sir, Import Policy for drugs is formulated in consideration of several factors such as demand, indigenous production, availability of viable indigenous technology etc.

(f) Import of individual drugs is not monitored by this Ministry.

Norms for conversion cost and packing charges

1343. SHRI H. HANUMANTHAPPA :
SHRIMATI PRATIBHA SINGH :

Will the Minister of PETROLEUM AND CHEMICALS be pleased to state :

(a) when were the norms for conversion cost and packing charges revised by Government ;

(b) what is the percentage increase and on what basis it was worked out ;

(c) whether it is a fact that several places conversion cost or even packing charges are much more than the material costs ;

(d) if so, what are the reasons therefor :

(e) whether it is a fact that revised norms are some adhoc increased over the earlier norms ;

(f) what are the norms of packing charges for ampoule upto 15 ml. and more that 15 ml. and on what basis these have been worked out ;

(g) whether it is a fact that norms allowed are much higher than the actuals ; and

(h) if so, what steps have been taken to rectify the anomaly ?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY) : (a) to (e) After the promulgation of the Drugs (Prices Control) Order, 1987, a Committee was constituted in September, 1987, under the Chairmanship of the then Director (Pharmaceutical Industry) for revision of conversion and packing norms. Based on the recommendations contained in the report of the norms committee, the revised norms for conversion cost, packing charges and process loss of material were announced in February, 1989 vide order S.O. No. 130(E) superceeding the earlier norms announced under DPCO, 1979 vide order S.O. 259(E) dated 3-5-1979.

(c) and (d) The material cost depends on price of bulk drug and excipient whereas the conversion cost and packing charges are unrelated to material cost and are more or less uniform for a particular type of formulation e.g. tablets, capsules. In case the price of the bulk drug is lower such situation may occur.

(f) It is Rs. 0·15 for both.

(g) and (h) No; Sir. While fixing the prices of formulations either the ceilings or the actuals, wherever is lower, are taken into account.

Multinational drug companies marketing products manufactured by Small Scale Units

1344. SMT. SATYA BAHIN : Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question 1348 given in the Rajya Sabha on the 21st May, 1990 and state :

(a) whether it is a fact that most of the major multinational companies are marketing a number of their products manufactured by small scale units without price approval ;

(b) if so, what are the names of 18 such major multinational drug companies, the names of the products of each and the present MRP of each ;

(c) whether it is also a fact that annual sales turn-over of certain small scale drug companies are much higher than the organised sector units ;

(d) what is the annual sales turn-over of five major small scale sector units ; and

(e) what are the details of other recommendations where his Ministry have taken independent decision ?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY) : (a) and (b) The requisite information, to the extent available, is given in the Annexed Statement. (*See* below).

(c) and (d) Sales turnover of individual units are not monitored.

(e) The requisite information has already been furnished in reply to Rajya Sabha Unstarred Question No. 868 answered on 13-8-1990.